Subject(s)
Esophageal Diseases , Esophagitis, Peptic , Esophagoscopy , Gastrointestinal Hemorrhage , Hemostasis, Surgical , Stents , Aged , Esophageal Diseases/diagnosis , Esophageal Diseases/etiology , Esophageal Diseases/surgery , Esophagitis, Peptic/complications , Esophagitis, Peptic/physiopathology , Esophagoscopy/adverse effects , Esophagoscopy/instrumentation , Esophagoscopy/methods , Esophagus/diagnostic imaging , Esophagus/pathology , Female , Gastrointestinal Hemorrhage/diagnosis , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/surgery , Hemostasis, Surgical/instrumentation , Hemostasis, Surgical/methods , Humans , Severity of Illness Index , Treatment OutcomeABSTRACT
Cathepsin K, a cysteine protease, is an essential enzyme in degradation of collagen type I. Since cathepsin K is relatively specific to osteoclasts, it represents a promising candidate for drug development. In the past decades, efforts have been made in developing highly potent, selective and orally applicable cathepsin K inhibitors. In contrast to balicatib and relacatib, whose drug development programmes were stopped due to cutaneous side-effects related to limited drug specificity, the more specific cathepsin K inhibitors odanacatib (ODN) and ONO-5334 have entered clinical trials. Odanacatib progressively increases bone mineral density (BMD) and decreases bone resorption markers in postmenopausal women with low BMD. Its clinical efficacy and safety was confirmed by several clinical studies but indicates that odanacatib is characterized by a resolution-of-effect with increases in bone resorption and rapid decreases in BMD following treatment discontinuation. A phase III fracture prevention study in postmenopausal women with osteoporosis is currently in the final phase.